297 related articles for article (PubMed ID: 36338164)
21. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
Shin DG; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee JH; Lee SH
Atherosclerosis; 2015 Nov; 243(1):53-8. PubMed ID: 26343872
[TBL] [Abstract][Full Text] [Related]
22. Past, Present, and Future of Familial Hypercholesterolemia Management.
Rocha VZ; Santos RD
Methodist Debakey Cardiovasc J; 2021; 17(4):28-35. PubMed ID: 34824679
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
24. Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography.
Lee WJ; Chuang HN; Chen YM; Liang KW; Tung H; Chen JP; Lee IT; Wang JS; Lin CH; Lin HJ; Sheu WH; Lee WL; Hsiao TH
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573395
[TBL] [Abstract][Full Text] [Related]
25. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
[TBL] [Abstract][Full Text] [Related]
26. Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study.
Ogura M; Harada-Shiba M; Masuda D; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S; Yamashita S
J Atheroscler Thromb; 2022 Jun; 29(6):906-922. PubMed ID: 34108342
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
[TBL] [Abstract][Full Text] [Related]
28. Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH.
Anagnostis P; Rizos CV; Skoumas I; Rallidis L; Tziomalos K; Skalidis E; Kotsis V; Doumas M; Kolovou G; Sfikas G; Garoufi A; Lambadiari V; Dima I; Kiouri E; Agapakis D; Zacharis E; Antza C; Kolovou V; Koumaras C; Bantouvakis G; Liamis G; Liberopoulos EN
Endocrine; 2022 May; 76(2):324-330. PubMed ID: 35262845
[TBL] [Abstract][Full Text] [Related]
29. Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia.
Du Z; Li F; Jiang L; Li L; Du Y; Yu H; Luo Y; Wang Y; Sun H; Hu C; Li J; Yang Y; Jiao X; Wang L; Qin Y
BMC Med; 2023 Jul; 21(1):275. PubMed ID: 37501168
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
[TBL] [Abstract][Full Text] [Related]
31. Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study.
Tada H; Kaneko H; Suzuki Y; Okada A; Takeda N; Fujiu K; Morita H; Ako J; Node K; Takeji Y; Takamura M; Yasunaga H; Komuro I
Eur J Clin Invest; 2024 Feb; 54(2):e14119. PubMed ID: 37916502
[TBL] [Abstract][Full Text] [Related]
32. Coronary artery event-free or resilient familial hypercholesterolemia: what's in a name?
Tamehri Zadeh SS; Chan DC; Mata P; Watts GF
Curr Opin Endocrinol Diabetes Obes; 2024 Jul; ():. PubMed ID: 38966915
[TBL] [Abstract][Full Text] [Related]
33. Familial Hypercholesterolemia and Lipoprotein Apheresis.
Makino H; Koezuka R; Tamanaha T; Ogura M; Matsuki K; Hosoda K; Harada-Shiba M
J Atheroscler Thromb; 2019 Aug; 26(8):679-687. PubMed ID: 31231083
[TBL] [Abstract][Full Text] [Related]
34. Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: An analysis from HELLAS-FH registry.
Barkas F; Rizos CV; Liamis G; Skoumas I; Garoufi A; Rallidis L; Kolovou G; Tziomalos K; Skalidis E; Sfikas G; Kotsis V; Doumas M; Anagnostis P; Lambadiari V; Anastasiou G; Koutagiar I; Attilakos A; Kiouri E; Kolovou V; Polychronopoulos G; Koutsogianni AD; Zacharis E; Koumaras C; Antza C; Boutari C; Liberopoulos E
J Clin Lipidol; 2024; 18(3):e394-e402. PubMed ID: 38331687
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels.
Funabashi S; Kataoka Y; Hori M; Ogura M; Doi T; Noguchi T; Harada-Shiba M
J Am Heart Assoc; 2022 Aug; 11(16):e025232. PubMed ID: 35929461
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
[TBL] [Abstract][Full Text] [Related]
37. Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia.
Tada H; Okada H; Nohara A; Yamagishi M; Takamura M; Kawashiri MA
Circ J; 2021 Oct; 85(11):2073-2078. PubMed ID: 34011825
[TBL] [Abstract][Full Text] [Related]
38. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
39. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.
Makover ME; Shapiro MD; Toth PP
Am J Prev Cardiol; 2022 Dec; 12():100371. PubMed ID: 36124049
[TBL] [Abstract][Full Text] [Related]
40. Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia.
Trinder M; Paquette M; Cermakova L; Ban MR; Hegele RA; Baass A; Brunham LR
Circ Genom Precis Med; 2020 Oct; 13(5):515-523. PubMed ID: 33079599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
